Linda Stein Gold, MD, director of dermatology clinical research at Henry Ford Health System, incoming vice president, American Academy of Dermatology (AAD), previews AAD 2022 and what she looks forward to both learning and teaching others.
Linda Stein Gold, MD, director of dermatology clinical research at Henry Ford Health System, incoming vice president, American Academy of Dermatology (AAD), previews AAD 2022 and what she looks forward to both learning and teaching others.
Transcript
What are you most looking forward to at the 2022 American Academy of Dermatology Annual Meeting?
I'm looking forward to a lot of things at AAD 2022. First of all, I'm looking forward to seeing my colleagues in person and catching up. And I'm also looking forward to really getting educated on the latest data in medical, pediatric, and cosmetic dermatology.
What can attendees expect to learn at AAD 2022?
The meeting is going to be very comprehensive, with updates in all areas of dermatology. I personally will be chairing the acne and rosacea symposium and I'll begin giving an update on what's new in topical therapy. I'll be giving some updates on what's new in acne and rosacea in general. I'll also be talking about some of the latest breakthroughs in topical therapy for psoriasis and, in one interesting session, I'll be talking about the challenges of conducting clinical trials, and specifically the challenge of patient recruiting.
What are some of the big issues in dermatology that you hope to see addressed?
There are a lot of issues in dermatology right now and Academy leadership has so much on their plates, but I think they've been doing a really good job in tackling some of our main issues. Some of these include scope of practice battles, the cost of both treating and not treating our patients, the 2022 changes in MIPS [Merit-based Incentive Payment System] and MACRA [Medicare Access and CHIP Reauthorization Act], and also helping us to restore faith in iPLEDGE [Risk Evaluation and Mitigation Strategy program]. We're also making a major push for DEI [diversity, equity, and inclusion].
Stagnation in Reimbursement Keeps Biomedical Innovation From Reaching All Patients, COA Panel Says
September 9th 2025Panelists at the Community Oncology Alliance Payer Exchange Summit discuss the urgent need for innovative reimbursement models in cancer care to match advancements in biomedical technology and drug discovery.
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
CNS Metastases in EGFR-Mutant NSCLC: Emerging Therapeutic Strategies and Ongoing Challenges
September 8th 2025Central nervous system (CNS) metastases in EGFR-mutant non–small cell lung cancer (NSCLC) remain a major challenge, with emerging therapies and evolving trial designs aiming to improve outcomes and address unmet needs.
Read More
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More